Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2005

View Archived Issues

Cenix and Instituto de Medicina Molecular work together in malaria

Pivotal phase III study begins for Technosphere Insulin

Enrollment nears completion in ARISE study of AGI-1067

Sumitomo licenses amrubicin hydrochloride to Conforma Therapeutics

First phase III study begins for Evizon in wet AMD

Peplin progresses PEP-005 Topical for actinic keratosis

Altana and Pfizer terminate Daxas collaboration

Paradigm signs agreement with Ortho-McNeil in pain and urinary incontinence

Agensys submits IND for phase I study of AGS-PSCA

Johnson & Johnson completes acquisition of Peninsula Pharmaceuticals

New approval for Topamax

Genzyme acquisition of Bone Care International approved by shareholders

Novel analgesics reported in patent literature

Procyon reflects on FY2004

Recent patents cover novel antiinfective agents

Valera seeks Danish approval for Vantas

SR Pharma to acquire Atugen

Factor Xa inhibitors, PAI-1 inhibitors in early development

ZK-187638 is neuroprotective after permanent focal cerebral ischemia in mice

SUN-N5147 mediates potent antiischemic effects in rats

Sant-7 potentiates the effect of dexamethasone against multiple myeloma

Fujisawa scientists discover selective and orally active IP receptor agonist

Kos inhaled insulin shows promise as adjunct therapy for type 2 diabetes

Preclinical evidence confirms the antidiabetic effects of CKD-501

SSR-180575 demonstrates antiischemic effects in cardiac ischemia model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...